

## **SECOND BLINDING EYE DISEASE PROGRAM – PRESENTATION OF CLINICAL DATA AT NOSA 2025**

- **PYC is progressing a drug candidate (known as PYC-001) that addresses the underlying cause of a blinding eye disease called Autosomal Dominant Optic Atrophy (ADOA) through clinical trials**
- **The Company today announces that it:**
  - **Has completed dosing of all ADOA patients in the Phase 1 Single Ascending Dose (SAD) study of PYC-001**
  - **Will present safety and early efficacy data from this SAD study at the Neuro-Ophthalmology Society of Australia (NOSA) conference in Auckland, NZ between 11-13 September 2025 highlighting:**
    - **Safety - No treatment-emergent serious adverse events in any patient dosed with PYC-001 to date; and**
    - **Efficacy – encouraging early trend towards improvement in measures of visual acuity in the PYC-001 treated eyes<sup>1</sup>**
- **PYC is now progressing PYC-001 into a global Phase 1/2 Multiple Ascending Dose (MAD) study that is anticipated to commence in Q4 2025<sup>2</sup>**

### **PERTH, Australia and SAN FRANCISCO, California – 5 September 2025**

PYC Therapeutics Limited (ASX:PYC) (PYC or the Company) is a precision medicine Company dedicated to changing the lives of patients with genetic diseases who have no treatment options available.

The Company currently has three clinical-stage drug development programs including a drug candidate (known as PYC-001) that addresses the underlying cause of a blinding eye disease called Autosomal Dominant Optic Atrophy (ADOA). ADOA affects 1 in every 35,000<sup>3</sup> people and there are currently no approved treatment options available for patients.

PYC today announces that it will be presenting data from the ongoing Phase 1 Single Ascending Dose (SAD) study in ADOA patients at the Neuro-Ophthalmology Society of Australia (NOSA) conference in Auckland, New Zealand between 11 and 13 September 2025.

---

<sup>1</sup> See details below

<sup>2</sup> Subject to the risks and uncertainties outlined in the Company's ASX filings of 17 February 2025

<sup>3</sup> Yu-Wai-Man, P. et al. The Prevalence and Natural History of Dominant Optic Atrophy Due to OPA1 Mutations Ophthalmology. 2010;117(8):1538-46 doi: 10.1016/j.ophtha.2009.12.038

The presentation will highlight the safety/tolerability profile of PYC-001 in the SAD study and the absence of any treatment-emergent serious adverse events in any patient dosed with the drug candidate to date. In addition, an encouraging early trend of improvement in measures of visual acuity in the treated-eye of patients enrolled in the SAD will also be presented.

A copy of the NOSA poster presentation is attached to this announcement.

## Next Steps

PYC is now preparing to progress into a global Multiple Ascending Dose (MAD) study of PYC-001 in patients with ADOA with an objective of establishing clinical proof-of-concept prior to progression into a global registrational trial directed towards supporting a New Drug Application for PYC-001 in ADOA. The global Phase 1/2 MAD study is expected to commence in Q4 of 2025.

## About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development <sup>4</sup>.

For more information, visit [pyctx.com](https://pyctx.com), or follow us on [LinkedIn](#) and [X](#).

## Forward looking statements

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*

*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

*This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited*

## CONTACT US

Investor relations and media contact  
[investor@pyctx.com](mailto:investor@pyctx.com)



<sup>4</sup> Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank  
<https://doi.org/10.1101/2020.11.02.2022232>



